Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Acer Therapeutics Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
- Exchange
- nasdaq
- Notice
- delisting notice
- Deficiency
- market value
- Rules
- 5550(b)(2)
Exact text from the filing
October 31, 2023, the Company, received a letter (the “Delisting Notification”) from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that Nasdaq will suspend trading in the Company’s common stock, $0.0001 par value per share (“Common Stock”), effective at the opening of trading on November 9, 2023, because the Company had not regained compliance with the Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”), which requires a listed company to have at least $35 million in market value of listed securities (“MVLS”) in order to qualify
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Acer Therapeutics Inc. amended First Amendment with Zevra Therapeutics, Inc. valued at $18,000,000 (effective 2023-10-31).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Zevra Therapeutics, Inc.
- Value
- $18,000,000
- Effective
- 2023-10-31
Exact text from the filing
On October 31, 2023, Acer Therapeutics Inc. (“Acer” or the “Company”) entered into an amendment (the “First Amendment”) to the Bridge Loan Agreement which amended that certain Bridge Loan Agreement dated as of August 30, 2023, (the “Bridge Loan Agreement”) by and between the Company and Zevra Therapeutics, Inc., a Delaware corporation (“Zevra”).
View on SEC.gov